Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05232682 · ClinicalTrials.gov registry record · Phase 2

Probiotics, Immune Function, and the Brain in Alcohol Consumers

A Phase 2 study, sponsored by Brown University.

Completed
Registry status
Phase 2
Development phase
32
Enrollment target

NCT05232682: Completed Phase 2 study, sponsored by Brown University.

NCT05232682 is a Phase 2 study that has completed, run by Brown University. The registered enrollment target is 32 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05232682, a Phase 2 study, has completed, sponsored by Brown University.

COMPLETED
Registry status
Phase 2
Development phase
32 participants
Enrollment target

Study Summary

This pilot project is a brief, open-label clinical trial of probiotics as an intervention in heavy drinkers. Heavy drinkers who do not yet show significant signs of liver disease may stand to benefit from probiotics, but no clinical trials to date have addressed this population. This study will recruit heavy drinkers to complete an open-label within-subjects trial. The study will investigate effects of probiotics on specific biomarkers in healthy heavy drinkers who currently are not seeking to change their alcohol use (i.e., are non-treatment-seeking).

Primary Outcome

LBP levels in plasma

Interventions

  • DIETARY_SUPPLEMENT Seed DS-01 Daily Synbiotic

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2022-02-24
Est. Completion 2023-08-09
Phase Phase 2
Brown University

231 total trials

What the finished NCT05232682 record still lists

NCT05232682 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% lower).

The record links to 0 conditions, and to 1 intervention - of which Seed DS-01 Daily Synbiotic is the first listed.

NCT05232682 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05232682 about?

NCT05232682 is a clinical study titled "Probiotics, Immune Function, and the Brain in Alcohol Consumers". This pilot project is a brief, open-label clinical trial of probiotics as an intervention in heavy drinkers. Heavy drinkers who do not yet show significant signs of liver disease may stand to benefit from probiotics, but no clinical trials to date have addressed this population. This study will recr...

What is the current status of trial NCT05232682?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2022-02-24. Estimated completion is 2023-08-09.

What interventions are being tested in trial NCT05232682?

The interventions under investigation include: Seed DS-01 Daily Synbiotic (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT05232682?

This trial is sponsored by Brown University, which has 231 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05232682's enrollment target sits among peer trials

32 1563rd of 2000 higher than 423 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02445781 · 32 participants · Early Phase 1

    Differing Levels of Hypoglycemia

  • NCT02792270 · 32 participants · NA

    Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT

  • NCT03068910 · 32 participants · Early Phase 1

    Hyperandrogenemia and Altered Day-night LH Pulse Patterns

  • NCT03208868 · 32 participants · NA

    Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05232682, the US trial registry maintained by the National Library of Medicine. NCT05232682 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.